Traders should monitor ZUSDURI's post-J Code sales acceleration in Q1 2026 as a key indicator of commercial traction. While JELMYTO shows stable growth, ZUSDURI's uptake and future guidance will be critical for sentiment. The debt refinancing improves liquidity but adds long-term interest obligations. Pipeline catalysts (UGN-103 NDA in H2 2026, UGN-501 IND by end of 2026) could drive future upside.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $19.02entry
- T+1 · 9mo ago −1.05%α −0.14% · $18.82
- T+5 · 8mo ago +4.68%α +5.89% · $19.91
- T+20 · 8mo ago −10.62%α −2.68% · $17.00
- T+60 · 6mo ago +54.89%α +45.56% · $29.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the commercial launch of ZUSDURI ($15.8M in sales) and 7% underlying growth in JELMYTO sales ($94M). The company refinanced its debt with Pharmakon Advisors for $200M in non-dilutive capital, strengthening its balance sheet. Despite higher R&D and SG&A expenses, management expressed confidence in ZUSDURI's launch trajectory following the January 2026 effective J Code, and provided 2026 JELMYTO sales guidance of $97M–$101M.
Key Financial Metrics
Key Facts
- ZUSDURI achieved $15.8 million in net sales in 2025, its first full year post-FDA approval (June 2025).
- JELMYTO generated $94.0 million in 2025, reflecting 7% year-over-year underlying demand growth.
- Total revenue increased 21% YoY to $109.8 million in 2025.
- Net loss widened to $153.5 million ($3.19/share) in 2025 from $126.9 million ($2.96/share) in 2024.
- Cash, cash equivalents, and marketable securities declined to $120.5 million as of December 31, 2025, from $241.7 million a year earlier.
- Company secured $200 million refinancing from Pharmakon Advisors, with a $50 million accordion option, at 8.25% fixed interest, repayment starting Q1 2030.
- 2026 JELMYTO sales guidance: $97M–$101M (3–7% growth); no ZUSDURI sales guidance provided.
- 2026 operating expense guidance: $240M–$250M, including $20M–$24M in share-based compensation.
- Phase 3 UTOPIA trial for UGN-103 showed 77.8% three-month complete response rate; NDA planned for H2 2026.
Financial Impact
Revenue grew 21% to $109.8M in 2025, but net loss increased to $153.5M. Operating expenses to remain elevated in 2026 at $240M–$250M. JELMYTO expected to grow modestly by $3M–$7M in 2026.
Risk Factors
- ZUSDURI is in early launch phase with limited sales visibility; reimbursement and adoption may lag expectations.
- Cash position decreased by over 50% YoY to $120.5M, raising potential future financing needs despite new debt.
- Operating losses are widening despite revenue growth, reflecting high commercial and R&D investments.
- Forward-looking statements dominate messaging; actual performance may fall short of management's optimistic tone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247313 |
Track record
16 reports on URGN
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers